Skip to main content
Erschienen in: Clinical Rheumatology 9/2020

26.03.2020 | Review Article

Cancer risks along the disease trajectory in antineutrophil cytoplasmic antibody associated vasculitis

verfasst von: Zaw Thet, Alfred K. Lam, Dwarakanathan Ranganathan, Soe Yu Aung, Tien K. Khoo

Erschienen in: Clinical Rheumatology | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

This review appraises the current literature on carcinogenic risks in anti-neutrophilic cytoplasmic autoantibody (ANCA) associated vasculitis (AAV). Patients with AAV are often at increased risk of developing non-melanoma skin carcinomas (NMSCs), haematological malignancies, bladder, breast, lung, prostate, and colorectal carcinomas. Reported cancer incidence in these patients ranged from 10 to 26%. Cancer risks at the time of diagnosis of AAV and disease outcomes along the trajectory of AAV that may lead to chronic kidney disease (CKD); dialysis and transplantation are summarized. Inherent carcinogenic risks as part of immunosuppressive treatment in AAV are further detailed with considerations on specific malignancy risks of therapeutic agents used. Challenges that contribute to malignancy risk include a high relapse rate of AAV and prolonged exposure to immunosuppressants. The incidence of malignancy increases significantly after 5 years of immunosuppressant exposure though risks in the earlier years have also been described. Following renal transplantation, there is limited information available on risk of malignancy. Thoughtful use of immunosuppressants, modification of lifestyle, and environmental factors, as well as adopting appropriate cancer screening will likely influence malignancy risk in individuals with AAV.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides. Arthritis Rheum 65(1):1–11PubMed Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides. Arthritis Rheum 65(1):1–11PubMed
2.
Zurück zum Zitat McAdoo SP, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2018;33(5):899 McAdoo SP, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2018;33(5):899
3.
Zurück zum Zitat Yoo J, Ahn SS, Jung SM, Song JJ, Park YB, Lee SW. Cancer development in Korean patients with ANCA-associated vasculitis: a single centre study. Clin Exp Rheumatol. 2018;36 Suppl 111(2):73–7 Yoo J, Ahn SS, Jung SM, Song JJ, Park YB, Lee SW. Cancer development in Korean patients with ANCA-associated vasculitis: a single centre study. Clin Exp Rheumatol. 2018;36 Suppl 111(2):73–7
4.
Zurück zum Zitat Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert JWC, Segelmark M, Guillevin L, Jayne D, European Vasculitis Society (2017) Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76(10):1662–1668PubMed Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert JWC, Segelmark M, Guillevin L, Jayne D, European Vasculitis Society (2017) Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76(10):1662–1668PubMed
5.
Zurück zum Zitat Thiel J, Troilo A, Salzer U, Schleyer T, Halmschlag K, Rizzi M, Frede N, Venhoff A, Voll RE, Venhoff N (2017) Rituximab as induction therapy in Eosinophilic Granulomatosis with Polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract 5(6):1556–1563PubMed Thiel J, Troilo A, Salzer U, Schleyer T, Halmschlag K, Rizzi M, Frede N, Venhoff A, Voll RE, Venhoff N (2017) Rituximab as induction therapy in Eosinophilic Granulomatosis with Polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract 5(6):1556–1563PubMed
6.
Zurück zum Zitat van Daalen EE, Rizzo R, Kronbichler A, Wolterbeek R, Bruijn JA, Jayne DR, Bajema IM, Rahmattulla C (2017) Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis 76(6):1064–1069PubMed van Daalen EE, Rizzo R, Kronbichler A, Wolterbeek R, Bruijn JA, Jayne DR, Bajema IM, Rahmattulla C (2017) Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis 76(6):1064–1069PubMed
7.
Zurück zum Zitat Sriskandarajah S, Bostad L, Myklebust TA, Moller B, Skrede S, Bjorneklett R (2017) Cancer in ANCA-associated glomerulonephritis: a registry-based cohort study. Int J Nephrol 2017:6013038PubMedPubMedCentral Sriskandarajah S, Bostad L, Myklebust TA, Moller B, Skrede S, Bjorneklett R (2017) Cancer in ANCA-associated glomerulonephritis: a registry-based cohort study. Int J Nephrol 2017:6013038PubMedPubMedCentral
8.
Zurück zum Zitat Sanders JS, de Joode AA, De Sevaux RG, Broekroelofs J, Voskuyl AE, van Paassen P, et al. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2016;31(9):1453–9 Sanders JS, de Joode AA, De Sevaux RG, Broekroelofs J, Voskuyl AE, van Paassen P, et al. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2016;31(9):1453–9
9.
Zurück zum Zitat Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P et al (2015) Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 74(1):177–184PubMed Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P et al (2015) Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 74(1):177–184PubMed
10.
Zurück zum Zitat Rahmattulla C, Berden AE, Wakker SC, Reinders ME, Hagen EC, Wolterbeek R, et al. Incidence of Malignancies in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed Between 1991 and 2013. Arthritis Rheum (Hoboken, NJ). 2015;67(12):3270–3278 Rahmattulla C, Berden AE, Wakker SC, Reinders ME, Hagen EC, Wolterbeek R, et al. Incidence of Malignancies in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed Between 1991 and 2013. Arthritis Rheum (Hoboken, NJ). 2015;67(12):3270–3278
11.
Zurück zum Zitat Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A et al (2015) Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford, England) 54(7):1153–1160 Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A et al (2015) Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford, England) 54(7):1153–1160
12.
Zurück zum Zitat McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R et al (2015) Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 30(Suppl 1):i123–i131 McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R et al (2015) Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 30(Suppl 1):i123–i131
13.
Zurück zum Zitat Faurschou M, Mellemkjaer L, Voss A, Keller KK, Hansen IT, Baslund B (2015) Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford, England) 54(8):1345–1350 Faurschou M, Mellemkjaer L, Voss A, Keller KK, Hansen IT, Baslund B (2015) Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford, England) 54(8):1345–1350
14.
Zurück zum Zitat Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371(19):1771–1780PubMed Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371(19):1771–1780PubMed
15.
Zurück zum Zitat Azar L, Springer J, Langford CA, Hoffman GS. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study. Arthritis Rheum (Hoboken, NJ). 2014;66(10):2862–2870 Azar L, Springer J, Langford CA, Hoffman GS. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study. Arthritis Rheum (Hoboken, NJ). 2014;66(10):2862–2870
16.
Zurück zum Zitat Pendergraft WF 3rd, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA et al (2014) Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 9(4):736–744PubMedPubMedCentral Pendergraft WF 3rd, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA et al (2014) Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 9(4):736–744PubMedPubMedCentral
17.
Zurück zum Zitat Calich AL, Puechal X, Pugnet G, London J, Terrier B, Charles P et al (2014) Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. J Autoimmun 50:135–141PubMed Calich AL, Puechal X, Pugnet G, London J, Terrier B, Charles P et al (2014) Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. J Autoimmun 50:135–141PubMed
18.
Zurück zum Zitat Charles P, Neel A, Tieulie N, Hot A, Pugnet G, Decaux O et al (2014) Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford, England) 53(3):532–539 Charles P, Neel A, Tieulie N, Hot A, Pugnet G, Decaux O et al (2014) Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford, England) 53(3):532–539
19.
Zurück zum Zitat Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR (2012) Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64(11):3760–3769PubMed Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR (2012) Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64(11):3760–3769PubMed
20.
Zurück zum Zitat Pullerits R, Ljevak M, Vikgren J, Bokarewa M (2012) Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single Centre. Scand J Immunol 76(4):411–420PubMed Pullerits R, Ljevak M, Vikgren J, Bokarewa M (2012) Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single Centre. Scand J Immunol 76(4):411–420PubMed
21.
Zurück zum Zitat Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71(6):955–960PubMed Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71(6):955–960PubMed
22.
Zurück zum Zitat Holle JU, Gross WL, Latza U, Nolle B, Ambrosch P, Heller M et al (2011) Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63(1):257–266PubMed Holle JU, Gross WL, Latza U, Nolle B, Ambrosch P, Heller M et al (2011) Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63(1):257–266PubMed
23.
Zurück zum Zitat Heijl C, Harper L, Flossmann O, Stucker I, Scott DG, Watts RA et al (2011) Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis study group clinical trials. Ann Rheum Dis 70(8):1415–1421PubMed Heijl C, Harper L, Flossmann O, Stucker I, Scott DG, Watts RA et al (2011) Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis study group clinical trials. Ann Rheum Dis 70(8):1415–1421PubMed
24.
Zurück zum Zitat Silva F, Seo P, Schroeder DR, Stone JH, Merkel PA, Hoffman GS, Spiera R, Sebastian JK, Davis JC Jr, St Clair EW, Allen NB, McCune W, Ytterberg SR, Specks U, Wegener's Granulomatosis Etanercept Trial Research Group (2011) Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum 63(8):2495–2503PubMedPubMedCentral Silva F, Seo P, Schroeder DR, Stone JH, Merkel PA, Hoffman GS, Spiera R, Sebastian JK, Davis JC Jr, St Clair EW, Allen NB, McCune W, Ytterberg SR, Specks U, Wegener's Granulomatosis Etanercept Trial Research Group (2011) Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum 63(8):2495–2503PubMedPubMedCentral
25.
Zurück zum Zitat Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211–220PubMed Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211–220PubMed
26.
Zurück zum Zitat Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232PubMedPubMedCentral Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232PubMedPubMedCentral
27.
Zurück zum Zitat Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B (2008) Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35(1):100–105PubMed Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B (2008) Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35(1):100–105PubMed
28.
Zurück zum Zitat Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, le Noach J, Khellaf M, Merrien D, Puéchal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L, French Vasculitis Study Group (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359(26):2790–2803PubMed Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, le Noach J, Khellaf M, Merrien D, Puéchal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L, French Vasculitis Study Group (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359(26):2790–2803PubMed
29.
Zurück zum Zitat Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J (1998) Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9(5):842–852PubMed Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J (1998) Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9(5):842–852PubMed
30.
Zurück zum Zitat Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116(6):488–498PubMed Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116(6):488–498PubMed
31.
Zurück zum Zitat Knight A, Askling J, Ekbom A (2002) Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 100(1):82–85PubMed Knight A, Askling J, Ekbom A (2002) Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 100(1):82–85PubMed
32.
Zurück zum Zitat Lam KY, Law SY, Chan KW, Yuen MC (1998) Glomerulonephritis associated with basaloid squamous cell carcinoma of the oesophagus. A possible unusual paraneoplastic syndrome. Scand J Urol Nephrol 32(1):61–63PubMed Lam KY, Law SY, Chan KW, Yuen MC (1998) Glomerulonephritis associated with basaloid squamous cell carcinoma of the oesophagus. A possible unusual paraneoplastic syndrome. Scand J Urol Nephrol 32(1):61–63PubMed
33.
Zurück zum Zitat Shang W, Ning Y, Xu X, Li M, Guo S, Han M, Zeng R, Ge S, Xu G (2015) Incidence of Cancer in ANCA-associated Vasculitis: a meta-analysis of observational studies. PLoS One 10(5):e0126016PubMedPubMedCentral Shang W, Ning Y, Xu X, Li M, Guo S, Han M, Zeng R, Ge S, Xu G (2015) Incidence of Cancer in ANCA-associated Vasculitis: a meta-analysis of observational studies. PLoS One 10(5):e0126016PubMedPubMedCentral
34.
Zurück zum Zitat Knight A, Askling J, Granath F, Sparen P, Ekbom A (2004) Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 63(10):1307–1311PubMedPubMedCentral Knight A, Askling J, Granath F, Sparen P, Ekbom A (2004) Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 63(10):1307–1311PubMedPubMedCentral
35.
Zurück zum Zitat Mahr A, Heijl C, Le Guenno G, Faurschou M (2013) ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol 27(1):45–56PubMed Mahr A, Heijl C, Le Guenno G, Faurschou M (2013) ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol 27(1):45–56PubMed
36.
Zurück zum Zitat Lowrance WT, Ordonez J, Udaltsova N, Russo P, Go AS (2014) CKD and the risk of incident cancer. J Am Soc Nephrol 25(10):2327–2334PubMedPubMedCentral Lowrance WT, Ordonez J, Udaltsova N, Russo P, Go AS (2014) CKD and the risk of incident cancer. J Am Soc Nephrol 25(10):2327–2334PubMedPubMedCentral
37.
Zurück zum Zitat Wong G, Hayen A, Chapman JR, Webster AC, Wang JJ, Mitchell P, Craig JC (2009) Association of CKD and cancer risk in older people. J Am Soc Nephrol 20(6):1341–1350PubMedPubMedCentral Wong G, Hayen A, Chapman JR, Webster AC, Wang JJ, Mitchell P, Craig JC (2009) Association of CKD and cancer risk in older people. J Am Soc Nephrol 20(6):1341–1350PubMedPubMedCentral
38.
Zurück zum Zitat Christensson A, Savage C, Sjoberg DD, Cronin AM, O'Brien MF, Lowrance W, Nilsson PM, Vickers AJ, Russo P, Lilja H (2013) Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. Int J Cancer 133(6):1452–1458PubMedPubMedCentral Christensson A, Savage C, Sjoberg DD, Cronin AM, O'Brien MF, Lowrance W, Nilsson PM, Vickers AJ, Russo P, Lilja H (2013) Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. Int J Cancer 133(6):1452–1458PubMedPubMedCentral
39.
Zurück zum Zitat Schollmeyer P, Bozkurt F (1988) The immune status of the uremic patient: hemodialysis vs CAPD. Clin Nephrol 30(Suppl 1):S37–S40PubMed Schollmeyer P, Bozkurt F (1988) The immune status of the uremic patient: hemodialysis vs CAPD. Clin Nephrol 30(Suppl 1):S37–S40PubMed
40.
Zurück zum Zitat Malachi T, Zevin D, Gafter U, Chagnac A, Slor H, Levi J (1993) DNA repair and recovery of RNA synthesis in uremic patients. Kidney Int 44(2):385–389PubMed Malachi T, Zevin D, Gafter U, Chagnac A, Slor H, Levi J (1993) DNA repair and recovery of RNA synthesis in uremic patients. Kidney Int 44(2):385–389PubMed
41.
Zurück zum Zitat Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB et al (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet (London, England) 354(9173):93–99 Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB et al (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet (London, England) 354(9173):93–99
42.
Zurück zum Zitat Nachman PH, Segelmark M, Westman K, Hogan SL, Satterly KK, Jennette JC, Falk R (1999) Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int 56(4):1544–1550PubMed Nachman PH, Segelmark M, Westman K, Hogan SL, Satterly KK, Jennette JC, Falk R (1999) Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int 56(4):1544–1550PubMed
43.
Zurück zum Zitat Cattran DCFJ, Cook HT, Liu ZH, Fervenza FC, Mezzano SA, Floege J, Nachman PH, Gipson DS, Praga M, Glassock RJ (2012) Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis Cattran DCFJ, Cook HT, Liu ZH, Fervenza FC, Mezzano SA, Floege J, Nachman PH, Gipson DS, Praga M, Glassock RJ (2012) Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis
44.
Zurück zum Zitat Gopaluni S, Smith RM, Lewin M, McAlear CA, Mynard K, Jones RB, Specks U, Merkel PA, Jayne DR, RITAZAREM Investigators (2017) Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials. 18(1):112PubMedPubMedCentral Gopaluni S, Smith RM, Lewin M, McAlear CA, Mynard K, Jones RB, Specks U, Merkel PA, Jayne DR, RITAZAREM Investigators (2017) Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials. 18(1):112PubMedPubMedCentral
45.
Zurück zum Zitat Kempen JH, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT et al (2008) Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 146(6):802–12.e1PubMedPubMedCentral Kempen JH, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT et al (2008) Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 146(6):802–12.e1PubMedPubMedCentral
46.
Zurück zum Zitat Kuschal C, Thoms KM, Schubert S, Schafer A, Boeckmann L, Schon MP et al (2012) Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair. Exp Dermatol 21(1):2–6PubMed Kuschal C, Thoms KM, Schubert S, Schafer A, Boeckmann L, Schon MP et al (2012) Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair. Exp Dermatol 21(1):2–6PubMed
47.
Zurück zum Zitat Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124(5):477–484PubMed Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124(5):477–484PubMed
48.
Zurück zum Zitat de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, EUVAS (European Vasculitis Study Group) (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150(10):670–680PubMed de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, EUVAS (European Vasculitis Study Group) (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150(10):670–680PubMed
49.
Zurück zum Zitat Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, Savage C, Pusey C, Jayne D (2004) Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15(3):717–721PubMed Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, Savage C, Pusey C, Jayne D (2004) Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15(3):717–721PubMed
50.
Zurück zum Zitat Rhee RL, Hogan SL, Poulton CJ, McGregor JA, Landis JR, Falk RJ, et al. Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease. Arthritis Rheum (Hoboken, NJ). 2016;68(7):1711–1720 Rhee RL, Hogan SL, Poulton CJ, McGregor JA, Landis JR, Falk RJ, et al. Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease. Arthritis Rheum (Hoboken, NJ). 2016;68(7):1711–1720
51.
Zurück zum Zitat Vamvakas S, Bahner U, Heidland A (1998) Cancer in end-stage renal disease: potential factors involved -editorial. Am J Nephrol 18(2):89–95PubMed Vamvakas S, Bahner U, Heidland A (1998) Cancer in end-stage renal disease: potential factors involved -editorial. Am J Nephrol 18(2):89–95PubMed
52.
Zurück zum Zitat Hibberd AD, Trevillian PR, Wlodarczyk JH, Kemp DG, Stein AM, Gillies AH, Heer MK, Sheil AG (2013) Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study. Transplantation. 95(1):122–127PubMed Hibberd AD, Trevillian PR, Wlodarczyk JH, Kemp DG, Stein AM, Gillies AH, Heer MK, Sheil AG (2013) Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study. Transplantation. 95(1):122–127PubMed
53.
Zurück zum Zitat Australia & New Zealand Dialysis and Trasnplant Registry: ANZDATA 41st Annual Report2018. https://www.anzdata.org.au/wpcontent/uploads/2018/11/c07_transplant_2017_v1.0_20181220.pdf Australia & New Zealand Dialysis and Trasnplant Registry: ANZDATA 41st Annual Report2018. https://​www.​anzdata.​org.​au/​wpcontent/​uploads/​2018/​11/​c07_​transplant_​2017_​v1.​0_​20181220.​pdf
54.
Zurück zum Zitat Tanriover B, Jaikaransingh V, MacConmara MP, Parekh JR, Levea SL, Ariyamuthu VK, Zhang S, Gao A, Ayvaci MU, Sandikci B, Rajora N, Ahmed V, Lu CY, Mohan S, Vazquez MA (2016) Acute rejection rates and graft outcomes according to induction regimen among recipients of kidneys from deceased donors treated with Tacrolimus and Mycophenolate. Clin J Am Soc Nephrol 11(9):1650–1661PubMedPubMedCentral Tanriover B, Jaikaransingh V, MacConmara MP, Parekh JR, Levea SL, Ariyamuthu VK, Zhang S, Gao A, Ayvaci MU, Sandikci B, Rajora N, Ahmed V, Lu CY, Mohan S, Vazquez MA (2016) Acute rejection rates and graft outcomes according to induction regimen among recipients of kidneys from deceased donors treated with Tacrolimus and Mycophenolate. Clin J Am Soc Nephrol 11(9):1650–1661PubMedPubMedCentral
55.
56.
Zurück zum Zitat Tessmer MS, Flaherty KT (2017) AACR Cancer Progress report 2017: harnessing research discoveries to save lives. Clin Cancer Res 23(18):5325PubMed Tessmer MS, Flaherty KT (2017) AACR Cancer Progress report 2017: harnessing research discoveries to save lives. Clin Cancer Res 23(18):5325PubMed
Metadaten
Titel
Cancer risks along the disease trajectory in antineutrophil cytoplasmic antibody associated vasculitis
verfasst von
Zaw Thet
Alfred K. Lam
Dwarakanathan Ranganathan
Soe Yu Aung
Tien K. Khoo
Publikationsdatum
26.03.2020
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 9/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-05055-x

Weitere Artikel der Ausgabe 9/2020

Clinical Rheumatology 9/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.